These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 20727957)

  • 1. Matrix tablets based on carrageenans with dual controlled release of doxazosin mesylate.
    Pavli M; Vrečer F; Baumgartner S
    Int J Pharm; 2010 Nov; 400(1-2):15-23. PubMed ID: 20727957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interactions of biopolymers carrageenans with cationic drug doxazosin mesylate characterized by means of differential scanning calorimetry.
    Pavli M; Vrecer F; Baumgartner S
    Pharmazie; 2010 Jul; 65(7):525-6. PubMed ID: 20662324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Doxazosin-carrageenan interactions: a novel approach for studying drug-polymer interactions and relation to controlled drug release.
    Pavli M; Baumgartner S; Kos P; Kogej K
    Int J Pharm; 2011 Dec; 421(1):110-9. PubMed ID: 21963476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Release mechanism of doxazosin from carrageenan matrix tablets: Effect of ionic strength and addition of sodium dodecyl sulphate.
    Kos P; Pavli M; Baumgartner S; Kogej K
    Int J Pharm; 2017 Aug; 529(1-2):557-567. PubMed ID: 28648579
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elucidation of release characteristics of highly soluble drug trimetazidine hydrochloride from chitosan-carrageenan matrix tablets.
    Li L; Wang L; Shao Y; Tian Y; Li C; Li Y; Mao S
    J Pharm Sci; 2013 Aug; 102(8):2644-54. PubMed ID: 23754467
    [TBL] [Abstract][Full Text] [Related]  

  • 6. pH-independent sustained release matrix tablet containing doxazosin mesylate: effect of citric acid.
    Cha KH; Tran TH; Kim MS; Kim JS; Park HJ; Park J; Cho W; Hwang SJ
    Arch Pharm Res; 2010 Dec; 33(12):2003-9. PubMed ID: 21191766
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Controlled-release tablet matrices from carrageenans: compression and dissolution studies.
    Hariharan M; Wheatley TA; Price JC
    Pharm Dev Technol; 1997 Nov; 2(4):383-93. PubMed ID: 9552467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of density functional theory in combination with FTIR and DSC to characterise polymer drug interactions for the preparation of sustained release formulations between fluvastatin and carrageenans.
    Karavas E; Koutris E; Papadopoulos AG; Sigalas MP; Nanaki S; Papageorgiou GZ; Achilias DZ; Bikiaris DN
    Int J Pharm; 2014 May; 466(1-2):211-22. PubMed ID: 24613179
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of cations on the microstructure and in-vitro drug release of κ- and ι-carrageenan liquid and semi-solid aqueous dispersions.
    Thrimawithana TR; Young S; Alany RG
    J Pharm Pharmacol; 2011 Jan; 63(1):11-8. PubMed ID: 21155810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel gelling systems of kappa-, iota- and lambda-carrageenans and their composite gels with cellulose using ionic liquid.
    Prasad K; Kaneko Y; Kadokawa J
    Macromol Biosci; 2009 Apr; 9(4):376-82. PubMed ID: 19003847
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of xanthan and its binary blends with synthetic polymers to design controlled release formulations of buccoadhesive nystatin tablets.
    Sakeer K; Al-Zein H; Hassan I; Martin GP; Nokhodchi A
    Pharm Dev Technol; 2010; 15(4):360-8. PubMed ID: 19772376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of polyelectrolyte counterion specificity, charge density, and conformation on polyelectrolyte-amphiphile interaction: the carrageenan/furcellaran-amitriptyline system.
    Hugerth A; Sundelöf LO
    Biopolymers; 2001 Feb; 58(2):186-94. PubMed ID: 11093117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix tablets of carrageenans. I. A compaction study.
    Picker KM
    Drug Dev Ind Pharm; 1999 Mar; 25(3):329-37. PubMed ID: 10071826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controlled-release matrix tablets of ibuprofen using cellulose ethers and carrageenans: effect of formulation factors on dissolution rates.
    Nerurkar J; Jun HW; Price JC; Park MO
    Eur J Pharm Biopharm; 2005 Sep; 61(1-2):56-68. PubMed ID: 15893919
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stability improvement of alpha-amylase entrapped in kappa-carrageenan beads: physicochemical characterization and optimization using composite index.
    Sankalia MG; Mashru RC; Sankalia JM; Sutariya VB
    Int J Pharm; 2006 Apr; 312(1-2):1-14. PubMed ID: 16500055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged intragastric drug delivery mediated by Eudragit® E-carrageenan polyelectrolyte matrix tablets.
    Bani-Jaber A; Al-Aani L; Alkhatib H; Al-Khalidi B
    AAPS PharmSciTech; 2011 Mar; 12(1):354-61. PubMed ID: 21302009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Matrix tablets of carrageenans. II. Release behavior and effect of added cations.
    Picker KM
    Drug Dev Ind Pharm; 1999 Mar; 25(3):339-46. PubMed ID: 10071827
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liquisolid technique as a new approach to sustain propranolol hydrochloride release from tablet matrices.
    Javadzadeh Y; Musaalrezaei L; Nokhodchi A
    Int J Pharm; 2008 Oct; 362(1-2):102-8. PubMed ID: 18647643
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro controlled release of sodium ferulate from Compritol 888 ATO-based matrix tablets.
    Li FQ; Hu JH; Deng JX; Su H; Xu S; Liu JY
    Int J Pharm; 2006 Nov; 324(2):152-7. PubMed ID: 16837152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of drug release kinetics of shellac-based matrix tablets by in-situ polymerization through annealing process.
    Limmatvapirat S; Limmatvapirat C; Puttipipatkhachorn S; Nunthanid J; Luangtana-anan M; Sriamornsak P
    Eur J Pharm Biopharm; 2008 Aug; 69(3):1004-13. PubMed ID: 18362064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.